{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:35:22Z","timestamp":1789061722770,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T00:00:00Z","timestamp":1179878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s10620-007-9839-8","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T17:58:53Z","timestamp":1179943133000},"page":"169-174","source":"Crossref","is-referenced-by-count":102,"title":["Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS"],"prefix":"10.1007","volume":"53","author":[{"given":"Janet","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Rang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,5,23]]},"reference":[{"key":"9839_CR1","volume-title":"The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment. A multinational consensus","author":"DA Drossman","year":"1994","unstructured":"Drossman DA (1994) The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment. A multinational consensus. Little, Brown, Boston"},{"key":"9839_CR2","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1053\/gast.1997.v112.agast972120","volume":"112","author":"DA Drossman","year":"1997","unstructured":"Drossman DA, Whitehead WE, Camilleri M (1997) Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 112:2120\u20132137","journal-title":"Gastroenterology"},{"key":"9839_CR3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0016-5085(80)90142-0","volume":"79","author":"WG Thompson","year":"1980","unstructured":"Thompson WG, Heaton KW (1980) Functional bowel disorders in apparently healthy people. Gastroenterology 79:283\u2013288","journal-title":"Gastroenterology"},{"key":"9839_CR4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(85)90525-2","volume":"2","author":"D Kumar","year":"1985","unstructured":"Kumar D, Wingate DL (1985) The irritable bowel syndrome: a paroxysmal motor disorder. Lancet 2:973\u2013977","journal-title":"Lancet"},{"key":"9839_CR5","first-page":"659","volume-title":"Neurogastroenterology from the basics to the clinics","author":"D Grundy","year":"2000","unstructured":"Grundy D (2000) Mechanisms for the symptoms of irritable bowel disease\u2014possible role of vagal afferents. In: Krammer H-J, Singer MV (eds) Neurogastroenterology from the basics to the clinics. Kluwer, Boston, pp 659\u2013663"},{"key":"9839_CR6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0016-5085(97)70220-8","volume":"112","author":"DHS Silverman","year":"1997","unstructured":"Silverman DHS, Munakata JA, Ennes H et al (1997) Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 112:64\u201372","journal-title":"Gastroenterology"},{"key":"9839_CR7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/gut.33.6.825","volume":"33","author":"WE Whitehead","year":"1992","unstructured":"Whitehead WE, Crowell MD, Robinson JC et al (1992) Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 33:825\u2013830","journal-title":"Gut"},{"key":"9839_CR8","first-page":"1143","volume":"45","author":"WG Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut 45:1143\u20131147","journal-title":"Gut"},{"key":"9839_CR9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"G Longstreth","year":"2006","unstructured":"Longstreth G, Thompson G, Chey W et al (2006) Functional bowel disorders. Gastroenterology 130:1480\u20131491","journal-title":"Gastroenterology"},{"key":"9839_CR10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0889-8553(21)00500-8","volume":"19","author":"PR Holt","year":"1990","unstructured":"Holt PR (1990) Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am 19:345\u2013359","journal-title":"Gastroenterol Clin North Am"},{"key":"9839_CR11","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","volume":"95","author":"M Pimentel","year":"2000","unstructured":"Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3503\u20133506","journal-title":"Am J Gastroenterol"},{"key":"9839_CR12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1572-0241.2003.07946.x","volume":"98","author":"M Pimentel","year":"2003","unstructured":"Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98:412\u2013418","journal-title":"Am J Gastroenterol"},{"key":"9839_CR13","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2036.2005.02690.x","volume":"22","author":"A Lupascu","year":"2005","unstructured":"Lupascu A, Gabrielli M, Lauritano EC et al (2005) Hydrogen glucose breath test to detect bacterial overgrowth: a prevalence case\u2013control study in irritable bowel syndrome. Aliment Pharmacol Ther 22:1157\u20131160","journal-title":"Aliment Pharmacol Ther"},{"key":"9839_CR14","first-page":"A460","volume":"128","author":"R McCallum","year":"2005","unstructured":"McCallum R, Schultz C, Sostarich S (2005) Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT). Gastroenterology 128:A460","journal-title":"Gastroenterology"},{"key":"9839_CR15","first-page":"A739","volume":"130","author":"I Posserud","year":"2006","unstructured":"Posserud I, Stotzer PO, Einar S et al (2006) Altered counts of small bowel bacteria in patients with irritable bowel syndrome. Gastroenterol 130:A739","journal-title":"Gastroenterol"},{"key":"9839_CR16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/BF01345304","volume":"25","author":"RB Drude","year":"1980","unstructured":"Drude RB, Finkelman D, Davis WD et al (1980) Malabsorption in jejunal diverticulosis treated with resection of the diverticula. Dig Dis Sci 25:802\u2013806","journal-title":"Dig Dis Sci"},{"key":"9839_CR17","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","volume":"325","author":"HC Soudah","year":"1991","unstructured":"Soudah HC, Hasier WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 325:1461\u20131467","journal-title":"N Engl J Med"},{"key":"9839_CR18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2036.2000.00751.x","volume":"14","author":"M Di Stefano","year":"2000","unstructured":"Di Stefano M, Malservisi S, Veneto G et al (2000) Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 14:551\u2013556","journal-title":"Aliment Pharmacol Ther"},{"key":"9839_CR19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0016-5085(99)70336-7","volume":"117","author":"A Attar","year":"1999","unstructured":"Attar A, Flourie B, Rambaud JC et al (1999) Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117:794\u2013797","journal-title":"Gastroenterology"},{"key":"9839_CR20","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1159\/000081990","volume":"51","author":"C Scarpignato","year":"2005","unstructured":"Scarpignato C, Pelosini I (2005) Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51:S36\u2013S66","journal-title":"Chemotherapy"},{"key":"9839_CR21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","volume":"101","author":"AI Sharara","year":"2006","unstructured":"Sharara AI, Aoun E, Abdul-Baki H et al (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326\u2013333","journal-title":"Am J Gastroenterol"},{"key":"9839_CR22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","volume":"145","author":"M Pimentel","year":"2006","unstructured":"Pimentel M, Park S, Kong Y, Kane SV (2006) Rifaximin, a non-absorbable antibiotic improves the symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Ann Intern Med 145:557\u2013563","journal-title":"Ann Intern Med"},{"key":"9839_CR23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1365-2036.2005.02493.x","volume":"21","author":"G Nucera","year":"2005","unstructured":"Nucera G, Gabrielli M, Lupascu A et al (2005) Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 21:1391\u20131395","journal-title":"Aliment Pharmacol Ther"},{"key":"9839_CR24","doi-asserted-by":"crossref","first-page":"A163","DOI":"10.1016\/S0016-5085(03)80815-6","volume":"124","author":"M Simren","year":"2003","unstructured":"Simren M, Ringstrom G, Agerforz P et al (2003) Small intestinal bacterial overgrowth is not of major importance in irritable bowel syndrome. Gastroenterology 124:A163","journal-title":"Gastroenterology"},{"key":"9839_CR25","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1111\/j.1572-0241.2003.08553.x","volume":"98","author":"KM Robson","year":"2003","unstructured":"Robson KM, Kakullavarapu J, Lembo T (2003) Bacterial overgrowth and irritable bowel syndrome: a look at prevalence, symptoms and quality of life. Am J Gastroenterol 98:S271","journal-title":"Am J Gastroenterol"},{"key":"9839_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11938-004-0022-4","volume":"7","author":"VV Singh","year":"2004","unstructured":"Singh VV, Toskes PP (2004) Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 7:19\u201328","journal-title":"Curr Treat Options Gastroenterol"},{"key":"9839_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0732-8893(93)90004-Q","volume":"16","author":"W Hoover","year":"1993","unstructured":"Hoover W, Gerlach E, Hoban D et al (1993) Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diag Microbiol Infect Dis 16:111\u2013118","journal-title":"Diag Microbiol Infect Dis"},{"key":"9839_CR28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","volume":"49","author":"JC Gillis","year":"1995","unstructured":"Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49:467\u2013484","journal-title":"Drugs"},{"key":"9839_CR29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-142-10-200505170-00005","volume":"142","author":"HL DuPont","year":"2005","unstructured":"DuPont HL, Jiang ZD, Okhuysen PC et al (2005) A randomized, double-blind, placebo-controlled trial of rifaximin to prevent traveler\u2019s diarrhea. Ann Intern Med 142:805\u2013812","journal-title":"Ann Intern Med"},{"key":"9839_CR30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","volume":"38","author":"A Mas","year":"2003","unstructured":"Mas A, Rodes J, Sunyer L et al (2003) Spanish association for the study of liver hepatic encephalopathy cooperative group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double dummy, controlled clinical trial. J Hepatol 38:51\u201358","journal-title":"J Hepatol"},{"key":"9839_CR31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","volume":"3","author":"L Gerard","year":"2005","unstructured":"Gerard L, Garey KW, DuPont HL (2005) Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 3:201\u2013211","journal-title":"Expert Rev Anti Infect Ther"},{"key":"9839_CR32","first-page":"S945","volume":"3","author":"HL DuPont","year":"2003","unstructured":"DuPont HL (2003) Community-acquired diarrheal disease in western countries: application of nonabsorbable oral antibiotic therapy. Adv Stud Med 3:S945\u2013S950","journal-title":"Adv Stud Med"},{"key":"9839_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2036.2005.02516.x","volume":"22","author":"EC Lauritano","year":"2005","unstructured":"Lauritano EC, Gabrielli M, Lupascu A et al (2005) Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 22:31\u201335","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-9839-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-007-9839-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-9839-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T02:19:05Z","timestamp":1628907545000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-007-9839-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["9839"],"URL":"https:\/\/doi.org\/10.1007\/s10620-007-9839-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,23]]}}}